Top

BMC Medical Informatics and Decision Making

Published in:

Open Access 01-12-2018 | Research article

Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment

Authors: Erik Berglund, Ragnar Westerling, Johan Sundström, Per Lytsy

Published in: BMC Medical Informatics and Decision Making | Issue 1/2018

Abstract

Background

Common measures used to describe preventive treatment effects today are proportional, i.e. they compare the proportions of events in relative or absolute terms, however they are not easily interpreted from the patient’s perspective and different magnitudes do not seem to clearly discriminate between levels of effect presented to people.

Methods

In this randomised cross-sectional survey experiment, performed in a Swedish population-based sample (n = 1041, response rate 58.6%), the respondents, aged between 40 and 75 years were given information on a hypothetical preventive cardiovascular treatment. Respondents were randomised into groups in which the treatment was described as having the effect of delaying a heart attack for different periods of time (Delay of Event, DoE): 1 month, 6 months or 18 months. Respondents were thereafter asked about their willingness to initiate such therapy, as well as questions about how they valued the proposed therapy.

Results

Longer DoE:s were associated with comparatively greater willingness to initiate treatment. The proportions accepting treatment were 81, 71 and 46% when postponement was 18 months, 6 months and 1 month respectively. In adjusted binary logistic regression models the odds ratio for being willing to take therapy was 4.45 (95% CI 2.72–7.30) for a DoE of 6 months, and 6.08 (95% CI 3.61–10.23) for a DoE of 18 months compared with a DoE of 1 month. Greater belief in the necessity of medical treatment increased the odds of being willing to initiate therapy.

Conclusions

Lay people’s willingness to initiate preventive therapy was sensitive to the magnitude of the effect presented as DoE. The results indicate that DoE is a comprehensible effect measure, of potential value in shared clinical decision-making.

Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol. 2004;58(5):528–35. https://doi.org/10.1111/j.1365-2125.2004.02202.x.CrossRefPubMedPubMedCentral

Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035–43. https://doi.org/10.1592/phco.2005.25.8.1035.CrossRefPubMed

Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88(3):229–33.CrossRef

Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. 2008;20(12):600–7. https://doi.org/10.1111/j.1745-7599.2008.00360.x.CrossRefPubMed

WHO. Adherence to Long-term Therapies: Evidence for action. Geneva: World Health Organization; 2003.

Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Mak. 1995;15(2):152–7.CrossRef

Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet. 1953;265(6796):1111–20; concl.CrossRef

Edwards A, Elwyn G, Stott N. Communicating risk reductions. Researchers should present results with both relative and absolute risks. BMJ. 1999;318(7183):603 author reply −4.PubMed

Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen IS, Nielsen JB. Danish GPs' perception of disease risk and benefit of prevention. Fam Pract. 2002;19(1):3–6.CrossRef

10.

Covey J. A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Mak. 2007;27(5):638–54. https://doi.org/10.1177/0272989X07306783.CrossRef

11.

Misselbrook D, Armstrong D. Patients' responses to risk information about the benefits of treating hypertension. Br J Gen Pract. 2001;51(465):276–9.PubMedPubMedCentral

12.

Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB. Laypersons' understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak. 2008;8:31. https://doi.org/10.1186/1472-6947-8-31.CrossRefPubMedPubMedCentral

13.

Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, et al. Using alternative statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev. 2011;(3):Cd006776. https://doi.org/10.1002/14651858.CD006776.pub2.

14.

Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011;103(19):1436–43. https://doi.org/10.1093/jnci/djr318.CrossRefPubMedPubMedCentral

15.

Christensen PM, Brosen K, Brixen K, Kristiansen IS. Expressing effects of osteoporosis interventions in terms of postponing of fractures. Eur J Clin Pharmacol. 2002;58(9):629–33. https://doi.org/10.1007/s00228-002-0526-6.CrossRefPubMed

16.

Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med. 2007;146(12):848–56.CrossRef

17.

Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther. 2003;25(10):2575–85.CrossRef

18.

Dahl R, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Bo Nielsen J. Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. BMC Med Inform Decis Mak. 2007;7:8. https://doi.org/10.1186/1472-6947-7-8.CrossRefPubMedPubMedCentral

19.

Lytsy P, Berglund L, Sundstrom J. A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events. Eur J Epidemiol. 2012;27(12):903–9. https://doi.org/10.1007/s10654-012-9752-0.CrossRefPubMedPubMedCentral

20.

Berglund E, Westerling R, Sundstrom J, Lytsy P. Treatment effect expressed as the novel delay of event measure is associated with high willingness to initiate preventive treatment - a randomized survey experiment comparing effect measures. Patient Educ Couns. 2016. https://doi.org/10.1016/j.pec.2016.07.028.CrossRef

21.

Bellavia A, Wallentin L, Orsini N, James SK, Cannon CP, Himmelmann A, et al. Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart. 2017;4(2):e000557. https://doi.org/10.1136/openhrt-2016-000557.CrossRefPubMedPubMedCentral

22.

Bottai M, Zhang J. Laplace regression with censored data. Biom J. 2010;52(4):487–503. https://doi.org/10.1002/bimj.200900310.CrossRefPubMed

23.

Sniderman PM, Grob DB. Innovations in experimental Design in Attitude Surveys. Annu Rev Sociol. 1996;22:377–99.CrossRef

24.

Gaines BJ, Kuklinski JH, Quirk PJ. The logic of the survey experiment reexamined. Polit Anal. 2007;15:1):1–20. https://doi.org/10.1093/pan/mpl008.CrossRef

25.

Lytsy P, Westerling R. Patient expectations on lipid-lowering drugs. Patient Educ Couns. 2007;67(1–2):143–50. https://doi.org/10.1016/j.pec.2007.03.004.CrossRefPubMed

26.

Berglund E, Lytsy P, Westerling R. Adherence to and beliefs in lipid-lowering medical treatments: a structural equation modeling approach including the necessity-concern framework. Patient Educ Couns. 2012. https://doi.org/10.1016/j.pec.2012.11.001.CrossRef

27.

Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24.CrossRef

28.

Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1):23–30. https://doi.org/10.1370/afm.238.CrossRefPubMedPubMedCentral

29.

Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17(1):17–32. https://doi.org/10.1080/08870440290001502.CrossRef

30.

Llewellyn CD, Miners AH, Lee CA, Harrington C, Weinman J. The illness perceptions and treatment beliefs of individuals with severe Haemophilia and their role in adherence to home treatment. Psychol Health. 2003;18(2):185–200. https://doi.org/10.1080/0887044031000098198.CrossRef

31.

Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology. 2005;44(6):762–7. https://doi.org/10.1093/rheumatology/keh587.CrossRefPubMed

32.

Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, et al. Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. Am Heart J. 2011;161(5):855–63. https://doi.org/10.1016/j.ahj.2011.02.009.CrossRefPubMed

33.

Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, et al. Changes in beliefs about medications during long-term care for ischemic heart disease. Am Heart J. 2010;159(4):561–9. https://doi.org/10.1016/j.ahj.2009.12.025.CrossRefPubMed

34.

Magadza C, Radloff SE, Srinivas SC. The effect of an educational intervention on patients' knowledge about hypertension, beliefs about medicines, and adherence. Res Social Adm Pharm. 2009;5(4):363–75. https://doi.org/10.1016/j.sapharm.2009.01.004.CrossRefPubMed

35.

Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, Rangarajan K, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005;39(11):1792–7. https://doi.org/10.1345/aph.1G249.CrossRefPubMed

36.

Jorgensen TM, Andersson KA, Mardby AC. Beliefs about medicines among Swedish pharmacy employees. Pharm World Sci. 2006;28(4):233–8. https://doi.org/10.1007/s11096-005-2907-2.CrossRefPubMed

37.

Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns. 2007;69(1–3):158–64. https://doi.org/10.1016/j.pec.2007.08.011.CrossRefPubMed

38.

Mardby AC, Akerlind I, Hedenrud T. Different development of general beliefs about medicines during undergraduate studies in medicine, nursing and pharmacy. Patient Educ Couns. 2009;75(2):283–9. https://doi.org/10.1016/j.pec.2008.10.012.CrossRefPubMed

39.

Mardby AC, Akerlind I, Hedenrud T. General beliefs about medicines among doctors and nurses in out-patient care: a cross-sectional study. BMC Fam Pract. 2009;10:35. https://doi.org/10.1186/1471-2296-10-35.CrossRefPubMedPubMedCentral

40.

Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers. 2011;15(12):871–5. https://doi.org/10.1089/gtmb.2011.0028.CrossRefPubMedPubMedCentral

41.

Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J Clin Epidemiol. 2002;55(9):888–92.CrossRef

42.

Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1. https://doi.org/10.1056/NEJMp1109283.CrossRefPubMed

43.

Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered care--ready for prime time. Eur J Cardiov Nursing. 2011;10(4):248–51. https://doi.org/10.1016/j.ejcnurse.2011.06.008.CrossRef

44.

Dorte G-H, Jes S. Discounting life-years: whither time preference? Health Economics. 1998;7(2):121–7. https://doi.org/10.1002/(SICI)1099-1050(199803)7:2<121::AID-HEC318>3.0.CO;2-H.CrossRef

Title: Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment
Authors: Erik Berglund
Ragnar Westerling
Johan Sundström
Per Lytsy
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Medical Informatics and Decision Making / Issue 1/2018
Electronic ISSN: 1472-6947
DOI: https://doi.org/10.1186/s12911-018-0662-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Evaluating hospital websites in Kuwait to improve consumer engagement and access to health information: a cross-sectional analytical study

Patient portal adoption and use by hospitalized cancer patients: a retrospective study of its impact on adverse events, utilization, and patient satisfaction

Development and pilot evaluation of a pregnancy-specific mobile health tool: a qualitative investigation of SmartMoms Canada

Presentation of laboratory test results in patient portals: influence of interface design on risk interpretation and visual search behaviour

Comprehensive user requirements engineering methodology for secure and interoperable health data exchange

A model for predicting utilization of mHealth interventions in low-resource settings: case of maternal and newborn care in Kenya